help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Postel-Vinay, M. C.
Right arrow Articles by Rappaport, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Postel-Vinay, M. C.
Right arrow Articles by Rappaport, R.

Journal of Clinical Endocrinology & Metabolism, Vol 73, 197-202, Copyright © 1991 by Endocrine Society


ARTICLES

Human plasma growth hormone (GH)-binding proteins are regulated by GH and testosterone

MC Postel-Vinay, A Tar, JF Hocquette, JP Clot, M Fontoura, R Brauner and R Rappaport
Unite de Biologie et Pathologie de la Croissance et du Developpement, INSERM Unite 30, Hopital des Enfants-Malades, Paris, France.

Possible regulation of GH-binding proteins (GH-BPs) in human plasma was examined. Eight children with isolated GH deficiency had a very low level of plasma GH-binding activity (10.2 +/- 1.1% of radioactivity). Under GH treatment the hormone binding to the high affinity BP (peak II- BP) increased in every patient to reach the mean value of 18.5 +/- 1.4%. In one patient, Scatchard plot analysis indicated that this increase was related to a higher binding capacity without any significant change in the binding affinity. A positive correlation existed between the GH-binding activity and insulin-like growth factor- I plasma levels. In nine boys with pubertal delay, the GH-specific binding to peak II-BP was normal (30.6 +/- 3.7% of radioactivity); it decreased significantly after testosterone treatment. In four boys with precocious puberty, the specific GH binding to peak II-BP was low (16.6 +/- 1.1%). It increased significantly to 21.6 +/- 1.1% of radioactivity after treatment with a LHRH analog. A negative correlation existed between plasma testosterone levels and GH binding to peak II-BP in boys presenting pubertal delay or precocious puberty. The high affinity GH- BP is regulated, and among the factors that play a role in this regulation, GH and testosterone have opposite effects.


This article has been cited by other articles:


Home page
EndocrinologyHome page
J.-L. Bresson, S. Jeay, M.-C. Gagnerault, C. Kayser, N. Beressi, Z. Wu, S. Kinet, M. Dardenne, and M.-C. Postel-Vinay
Growth Hormone (GH) and Prolactin Receptors in Human Peripheral Blood Mononuclear Cells: Relation with Age and GH-Binding Protein
Endocrinology, July 1, 1999; 140(7): 3203 - 3209.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Tonshoff, M. J. Cronin, M. Reichert, D. Haffner, A.-M. Wingen, W. F. Blum, and O. Mehls
Reduced Concentration of Serum Growth Hormone (GH)-Binding Protein in Children with Chronic Renal Failure: Correlation with GH Insensitivity
J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1007 - 1013.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1991 by The Endocrine Society